- Home
- Publications
- Publication Search
- Publication Details
Title
Centrally Acting Agents for Obesity: Past, Present, and Future
Authors
Keywords
-
Journal
DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-16
DOI
10.1007/s40265-018-0946-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
- (2018) Vaia Lambadiari et al. Cardiovascular Diabetology
- The therapeutic potential of targeting the peripheral endocannabinoid/CB 1 receptor system
- (2018) Joseph Tam et al. European Journal of Internal Medicine
- Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy
- (2018) Candida J. Rebello et al. Obesity
- Progress and challenges in anti-obesity pharmacotherapy
- (2018) Daniel H Bessesen et al. Lancet Diabetes & Endocrinology
- Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity
- (2017) Kathryn M Hurren et al. Expert Opinion on Drug Metabolism & Toxicology
- Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample
- (2017) M Dalton et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C
- (2017) Caleb C. Lord et al. JOURNAL OF CLINICAL INVESTIGATION
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study
- (2017) Steven R. Smith et al. Obesity
- Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis
- (2017) Carel le Roux et al. Obesity Facts
- Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines
- (2017) Z. Dong et al. Obesity Reviews
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling
- (2017) Joseph Tam et al. Molecular Metabolism
- Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial
- (2016) Olivia M. Farr et al. DIABETES
- Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
- (2016) J. Ard et al. DIABETES OBESITY & METABOLISM
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy
- (2016) K Fujioka et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
- (2016) Peter Kühnen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers
- (2016) Ken Fujioka et al. Obesity
- Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials
- (2016) Neil J. Weissman et al. Obesity
- Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia
- (2016) Richard Nesto et al. POSTGRADUATE MEDICINE
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study
- (2015) Mojca Jensterle et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
- (2015) Eva W. Iepsen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot study
- (2015) Sarah Anne Robert et al. Obesity Research & Clinical Practice
- Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?
- (2015) Ronette L. Kolotkin et al. QUALITY OF LIFE RESEARCH
- Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release
- (2014) W. Timothy Garvey et al. DIABETES CARE
- Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes
- (2014) Steven R. Smith et al. Obesity
- Cost-Effectiveness Analysis of Qsymia for Weight Loss
- (2014) Eric A. Finkelstein et al. PHARMACOECONOMICS
- Topiramate use in pregnancy and the birth prevalence of oral clefts
- (2014) Daniel Mines et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The insulin sensitizing effect of topiramate involves KATPchannel activation in the central nervous system
- (2013) C P Coomans et al. BRITISH JOURNAL OF PHARMACOLOGY
- Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
- (2013) W. Timothy Garvey et al. DIABETES CARE
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity
- (2013) S. R. Smith et al. DIABETES OBESITY & METABOLISM
- Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET
- (2013) Lieuwe Appel et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats
- (2013) Bo Hjorth Bentzen et al. Obesity
- Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
- (2013) Louis J. Aronne et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat
- (2013) Henrik H. Hansen et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
- (2012) Patrick M. O'Neil et al. Obesity
- A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults
- (2012) David H. Winslow et al. SLEEP
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
- (2011) Kana Inoue et al. Cardiovascular Diabetology
- Evaluation of the Abuse Potential of Lorcaserin, a Serotonin 2C (5-HT2C) Receptor Agonist, in Recreational Polydrug Users
- (2011) M J Shram et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
- (2011) Meredith C. Fidler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Effect of Tesofensine on Appetite Sensations
- (2011) Jo-Anne Gilbert et al. Obesity
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users
- (2010) K A Schoedel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
- (2010) A Sjödin et al. INTERNATIONAL JOURNAL OF OBESITY
- Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure
- (2010) Corby K. Martin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat
- (2010) Anne Marie D Axel et al. NEUROPSYCHOPHARMACOLOGY
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
- (2009) Sten Madsbad BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Serotonergic drugs and valvular heart disease
- (2009) Richard B Rothman et al. Expert Opinion On Drug Safety
- Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
- (2009) Frank L. Greenway et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
- (2008) Arne Astrup et al. LANCET
- Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease
- (2008) Arne Astrup et al. Obesity
- Rational Design of a Combination Medication for the Treatment of Obesity
- (2008) Frank L. Greenway et al. Obesity
- Lorcaserin (APD356), a Selective 5-HT2CAgonist, Reduces Body Weight in Obese Men and Women
- (2008) Steven R. Smith et al. Obesity
- Contribution of the active metabolite M1 to the pharmacological activity of tesofensinein vivo: a pharmacokinetic-pharmacodynamic modelling approach
- (2007) T Lehr et al. BRITISH JOURNAL OF PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started